New Immunotherapy Drugs Targeting LAG-3 Show Great Promise
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 23 June 2021 In News, Science, Treatment
Researchers presented a series of highly encouraging clinical trial results at the recent American Society for Clinical Oncology (ASCO) annual meeting that suggest that new drugs targeting the protein LAG-3 – developed by BMS and Regeneron – may be an important addition to the current treatment arsenal.
Averting and Treating Immune-related Adverse Events Associated with Checkpoint Immunotherapies
Checkpoint inhibitors are therapies that empower the immune system to kill cancer cells. However, sometimes immune-related adverse events (irAE) can also occur as a result. To help overcome this challenge, MRA has issued a number of research grants, including some in partnership with the American Cancer Society (ACS) and the Society for Immunotherapy of Cancer (SITC), to support an array of approaches.
Advancing Melanoma Research in Times of Uncertainty
Each year, the annual MRA Scientific Retreat brings hundreds of people from across the melanoma research ecosystem together to exchange ideas, report on scientific progress, celebrate achievements, and mourn the losses. In these ways, the 2021 Retreat was no different.
Separating Hope From Hype in Melanoma Research
In the last decade alone 13 therapeutic approaches have earned FDA approval giving patients, families, and clinicians new tools to treat melanoma. But there can be a fine line between hope and hype, especially today when news — both true and inflated — travels instantly via the internet and social media.
MRA's Acral Melanoma Cell Line Catalog: A Launching Pad for Research
In a collaborative effort to facilitate research focused on acral melanoma, MRA has created and annotated a catalog of acral melanoma cell lines from various institutions worldwide. The catalog includes cell lines created by researchers at Memorial Sloan Kettering Cancer Center, Wistar Institute, Yale University, the University of Zurich, the Queensland Institute of Medical Research in Australia and more.
Turning Memory Into Action: Honoring Her Father and Raising Awareness
By Renee Orcione, MRA Development Associate | 24 May 2021
In 2021, 7,180 people are estimated to lose their lives due to melanoma in the United States alone. That’s 7,180 individuals – fathers, mothers, daughters, sons, partners and more – gone but for the impact they had, and the memories and loved ones that they left behind. Those left behind, be it family...
Firming the Foundation: Pathology, Rare Melanomas, and Moving the Field Forward
When Dr. Priyadharsini Nagarajan talks about her work at MD Anderson Cancer Center, her energy and excitement could light up any room. That’s because Dr. Nagarajan – a pathologist who specializes in skin (called a ‘dermatopathologist’) – sees her work as critical to creating a firm foundation for all subsequent...
SPOTMYUV: Your Sunscreen’s New Best Friend
SPOTMYUV, a small, water-resistant sticker applied to any skin exposed to direct sunlight such as your arm or shoulder, helps the wearer know when it is time to reapply their sunscreen by changing color. Throughout the day, a SPOT sticker works to absorb the sunscreen’s UV protecting ingredients at about the same rate as your skin. The SPOT is clear when you are protected by your sunscreen and quickly turns into a deep purple as the sunscreen loses its effectiveness. By monitoring the SPOT, you get a real-time way to monitor your sunscreen without chancing sunburn.
Melanoma Research Alliance Announces $8.1 million in Research Awards
The Melanoma Research Alliance, the largest non-profit funder of melanoma research, is proud to announce $8.1 million in funding for 34 new research awards. The awards, issued on the cusp of Melanoma Awareness Month, provide critical funding to address urgent unmet needs in melanoma.
A New Treatment Approach in the Arsenal: Neoadjuvent Therapy
Surgery is the backbone of melanoma treatment and is curative for the vast majority of patients with localized melanoma. However, even if surgery successfully removes all detectible traces of tumor tissue, some patients will still experience a melanoma relapse. Can neoadjuvant therapy, an experimental approach, reduce the risk of recurrence?